Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission.

IMPORTANCE Ear, nose, and throat (ENT) lesions are frequently involved in Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), although a detailed description is lacking in the literature. OBJECTIVES To describe ENT lesions at the acute stage and follow-up in a large series of patients with SJS/TEN and identify factors associated with the severe ENT form. DESIGN, SETTING, AND PARTICIPANTS Retrospective study of 49 patients with SJS/TEN hospitalized in a referral care center from 2005 to 2010. Patients who underwent a full ENT workup including examination and a nasal fiberoptic endoscopy by an otorhinolaryngologist in the acute phase and during follow-up at 2 and 12 months were included in the study. MAIN OUTCOMES AND MEASURES Recorded variables included maximal body surface area (BSA) detachment, SCORTEN (Score of Toxic Epidermal Necrosis [a severity of illness score]), sites and type of ENT mucosal lesions, intensive care unit transfer, pulmonary infection, and mortality. "Severe ENT form" was defined by the occurrence of laryngeal lesions with the risk of airways obstruction. Clinical characteristics associated with severe ENT form were analyzed in univariate and multivariable analysis. RESULTS Of the 49 patients who underwent a full ENT workup (female to male ratio, 1.1:1), ENT symptoms (eg, odynophagia, dysphagia, dysphonia, dyspnea, earache, nasal obstruction) occurred in 48 (98%). Dyspnea or dysphonia were significantly associated with severe ENT form (21% [P = .03] and 50% [P < .001], respectively). Topographic frequencies of lesions were as followed: lips and oral cavity (n = 46 [93%]) and pharynx and vestibule of the nose (n = 26 [53%]). Fourteen patients (29%) had severe ENT form. Findings for other recorded variables for those with vs without ENT examination are as follows: maximal BSA detachment (20% [0%-95%] vs 5.5% [0%-95%]; P = .004), SCORTEN (1 [0-5] vs 1 [0-5]; P = .54), intensive care unit transfer (10 [20%] vs 9 [19%]; P = .80), pulmonary infection (9 [18%] vs 6 [13%]; P = .10), and mortality (3 [6%] vs 5 [10%]; P = .70). In multivariable analysis, pulmonary infection was significantly associated with severe ENT form (odds ratio, 5.9 [95% CI, 1.1-32.8] [P = .04]). After remission of SJS/TEN, a complete ENT mucosal healing occurred in 36 patients (74%) at 2 months and in nearly all patients (n = 48 [98%]) at 1 year of follow-up. CONCLUSIONS AND RELEVANCE Severe ENT form is associated with pulmonary infection and is easily detected by nasal fiberoptic endoscopy. ENT evaluation should be suggested when dysphonia or dyspnea is observed at the acute stage of SJS/TEN.

[1]  C. Brun-Buisson,et al.  Acute Respiratory Failure in Patients With Toxic Epidermal Necrolysis: Clinical Features and Factors Associated With Mechanical Ventilation* , 2014, Critical care medicine.

[2]  R. Lefering,et al.  27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. , 2013, Burns : journal of the International Society for Burn Injuries.

[3]  L. Naldi,et al.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[4]  Somchai Yongsiri,et al.  Characteristics of toxic epidermal necrolysis and Stevens-Johnson syndrome: a 5-year retrospective study. , 2013, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[5]  B. Pollock,et al.  Toxic epidermal necrolysis: five years of treatment experience from a burn unit. , 2012, Journal of the American Academy of Dermatology.

[6]  R. Zajíček,et al.  Toxic epidermal necrolysis and Stevens‐Johnson syndrome at the Prague Burn Centre 1998–2008 , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  H. Benchikhi,et al.  [Stevens-Johnson and Lyell syndromes: mucocutaneous and ocular sequels in 43 cases]. , 2011, Annales de dermatologie et de venereologie.

[8]  N. Moiemen,et al.  Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre , 2010, Clinical and experimental dermatology.

[9]  J. Roujeau,et al.  Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis , 2010, The British journal of dermatology.

[10]  A. Dunant,et al.  ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis , 2010, Clinical pharmacology and therapeutics.

[11]  J. Roujeau,et al.  Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. , 2009, Archives of Dermatology.

[12]  G. Soubrane,et al.  Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2009, Archives of dermatology.

[13]  L. Naldi,et al.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. , 2002, Archives of dermatology.

[14]  J. Roujeau,et al.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.

[15]  J. Roujeau,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.

[16]  J. Roujeau,et al.  Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study , 1997, Intensive Care Medicine.

[17]  J. Roujeau,et al.  Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. , 1995, Archives of dermatology.

[18]  Michael Stewart,et al.  Head and Neck Manifestations of Erythema Multiforme in Children , 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[19]  W. Koch,et al.  Stevens-Johnson syndrome with supraglottic laryngeal obstruction. , 1989, Archives of otolaryngology--head & neck surgery.

[20]  J. Parsons Management of toxic epidermal necrolysis. , 1985, Cutis.

[21]  Y. Tay,et al.  Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. , 2012, Acta dermato-venereologica.

[22]  H. Benchikhi,et al.  [Stevens-Johnson and Lyell syndromes: mucocutaneous and ocular sequels in 43 cases]. , 2011, Annales de dermatologie et de venereologie.

[23]  M. Mockenhaupt,et al.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.

[24]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[25]  R. Rogers,et al.  Oral manifestations of erythema multiforme. , 2003, Dermatologic clinics.

[26]  R. Stern,et al.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.